What is OncoHost?
OncoHost operates at the intersection of life sciences and artificial intelligence, specializing in the development of personalized cancer therapy strategies. The company's core innovation, the PROphet platform, utilizes proteomic analysis of blood samples to monitor biological processes induced by the patient in response to cancer treatment. By identifying unique host response profiles, OncoHost enables clinicians to predict individual patient outcomes with greater accuracy, thereby facilitating more effective, rationalized combination therapies and identifying novel drug targets. This approach addresses the critical clinical hurdle of therapy resistance, positioning OncoHost as a transformative force in the oncology sector.
How much funding has OncoHost raised?
OncoHost has raised a total of $43M across 2 funding rounds:
Series B
$8M
Series C
$35M
Series B (2021): $8M with participation from OurCrowd
Series C (2022): $35M led by Menora Mivtachim, ALIVE Israel HealthTech VC, Leumi Partners, and OurCrowd
Key Investors in OncoHost
Menora Mivtachim
Menora Mivtachim Holdings is a prominent Israeli insurance and finance group with extensive experience in asset management and large-scale pension fund operations.
Leumi Partners
Leumi Partners is a premier Israeli merchant and investment banking platform specializing in strategic direct investments, underwriting, and technology-focused financial advisory.
OurCrowd
OurCrowd is a leading global investment platform that connects accredited investors and institutions with high-growth startups and venture funds.
What's next for OncoHost?
With the recent infusion of capital, OncoHost is poised to deepen its clinical validation efforts and broaden the commercial application of its PROphet platform. The strategic roadmap likely includes expanding the platform's utility across diverse cancer types and strengthening partnerships with global pharmaceutical entities to integrate proteomic insights into drug development pipelines. As the company scales, the focus will shift toward establishing its technology as a standard of care in personalized oncology, leveraging its data-rich environment to refine predictive models and enhance the efficacy of existing therapeutic regimens. The firm's ability to translate complex biological data into actionable clinical insights remains its primary competitive advantage in a rapidly evolving healthcare market.
See full OncoHost company page
